

Index

- acetaminophen. *See* paracetamol
 acetylcholinesterase inhibitors, 103
 adjusted body weight (ABW), 134
 adjuvant medications
 balanced anaesthesia concept, 73, 74
 clonidine, 74
 dexmedetomidine, 74–5
 ketamine, 75–6
 lidocaine, 76
 magnesium, 75
 neurological mechanisms of anaesthesia, 73–4
 suppressing consciousness, connectedness and responsiveness, 73–4
 use in TIVA, 73
 administration of anaesthetic drugs
 history of, 46
 advanced TIVA, 162
 alternatives to remifentanyl, 162–3
 neuronal apoptosis with intravenous agents, 164
 obstetric case scenarios, 164–8
 paediatric parameter sets, 164
 relationship between drug concentration and effect (Hill equation), 164
 $t_{1/2}$ keo (equilibration half-time) in paediatric patients, 163–4
 TCI with alfentanil, 162–3
 TCI with fentanyl, 163
 TCI with sufentanil, 163
 alfentanil, 18, 19, 41
 context sensitive half-time, 20
 elimination half-life, 20
 keo, 11
 Maitre model, 36
 pharmacokinetic parameter sets, 31
 Scott model, 35–6
 titration, 45
 use in TCI, 162–3
 algorithms
 development of, 48–9
 used to programme syringe pumps, 46–7
 See also pharmacokinetic models
 alpha-2 agonists, 74–5
 analgesic properties, 88
 concerns, 88
 mechanism of action, 88
 timing/dosage, 88
 TIVA benefits, 88
 anaesthesia induction
 approaches to, 54–6
 anaesthetic drug modelling systems, 60
 anaesthetic drug administration
 history of, 46
 anaesthetic drugs
 importance of titration, 14
 therapeutic index, 14
 analgesia
 analgesic supplements for TIVA, 19
 during recovery from TIVA, 102
 preventive analgesia, 80
 analgesia nociception index (ANI), 69
 analgesic regimen model, 80–94
 alpha-2 agonists, 88
 clonidine, 88
 dexamethasone, 83–4
 dexmedetomidine, 88
 epidural analgesia, 86
 example case scenario, 91–4
 expected post-operative pain, 80
 fentanyl, 89, 90–1
 gabapentin, 83
 hydromorphone, 91
 intra-operative analgesia options, 87–91
 ketamine, 87–8
 lidocaine IV, 87
 local anaesthetics, 85–7
 local infiltration of local anaesthetics, 85–7
 methadone, 89–90
 morphine, 91
 nature of the surgery, 80
 neuromodulators, 83
 NSAIDs (non-steroidal anti-inflammatory drugs), 82
 opioid drugs, 84–5
 paracetamol, 81–2
 patient requirements, 80
 peripheral nerve blocks (PNB), 85–6
 pregabalin, 83
 pre-operative analgesia options, 80–7
 remifentanyl, 87, 89
 steroids, 83–4
 sufentanil, 89
 tapentadol, 85
 tramadol, 85
 transition opioids, 87, 90–1
 anti-emetic action
 propofol, 25
 Apfel criteria, 103
 apnoeic ventilation, 107
 aspirin, 82
 atropine, 103
 awareness under anaesthesia
 advantages of DOA monitoring, 67–9
 contributing factors, 63–5
 correlates with DOA monitor indices, 66–7
 EEG patterns under TCI TIVA, 65–6
 limitations of DOA monitoring, 69
 nociception monitoring, 69
 practical aspects of DOA monitoring, 69–70
 rationale behind depth of anaesthesia monitoring, 65
 risk during TIVA, 44, 63–5
 scope of the problem, 63–5
 what depth of anaesthesia monitors measure, 65–6
 balanced anaesthesia, 19, 58, 73, 74
 bio-phase, 8
 BIS index, 12, 65, 66, 67
 BIS™ monitor, 44, 51, 61, 96, 115
 blood-effect equilibration constant. *See* keo
 BMI (body mass index) classification, 132, 133
 Bovill model, 32
 burst suppression ratio (BSR), 65, 66
 cancer
 anti-tumour properties of propofol, 1
 cancer surgery
 volatile versus intravenous anaesthesia, 1
 cardiovascular system
 effects of propofol, 25
 celecoxib, 82
 central nervous system

- effects of propofol, 24–5
- climate change. *See* environmental impacts
- clonidine
 - adjuvant medication in TIVA, 74
 - analgesic properties, 88
 - concerns, 88
 - mechanism of action, 88
 - opioid-sparing adjuvant, 102–3
 - timing/dosage, 88
 - TIVA benefits, 88
- compartments, 5–6
- computer-assisted sedation systems, 158–9
- connectedness
 - suppression in anaesthesia, 73–4
- Conox™ monitor, 44, 66, 96
- consciousness
 - suppression in anaesthesia, 73–4
- context sensitive half-time, 6, 19–21, 125
- cricoid pressure, 106, 107
- cytochrome P450 3A4 enzyme
 - inhibition by propofol, 23
- decrement time
 - definition, 97–8
 - distinction from half-life, 98–9
 - how to calculate, 99–100
 - how to use to guide anaesthetic management, 100–1
 - why it changes over time, 99–100
- decrement time function
 - definition, 97–8
- delivery sets for TIVA, 50–1
- Deltasorb™ anaesthetic drug recovery system, 150
- depth of anaesthesia indices
 - correlates with, 66–7
- depth of anaesthesia monitoring, 51
 - advantages of, 67–9
 - EEG monitoring, 65
 - EEG patterns under TCI TIVA, 65–6
 - limitations, 69
 - nociception monitoring, 69
 - paediatric TIVA, 115
 - placement of scalp electrodes, 69–70
 - practical aspects, 69–70
 - rationale behind, 65
 - to help recovery from TIVA, 96
- depth of anaesthesia monitors
 - what they measure, 65–6
- desflurane, 1, 148, 149, 150
- dexamethasone
 - analgesic properties, 83–4
- dexmedetomidine, 36, 44
 - adjuvant medication in TIVA, 74–5
 - analgesic properties, 88
 - concerns, 88
 - mechanism of action, 88
- neuroprotective effects, 74–5
- pharmacokinetics and pharmacodynamics, 12
- pharmacokinetics for obese patients, 136
- timing/dosage, 88
- TIVA benefits, 88
- use for sedation, 157
- use in pregnant patients, 141
- diclofenac, 82, 102
- difficult airway cases, 54
- Diprifusor™, 47
 - development of, 15
 - Marsh model, 17, 19
 - predicted versus actual concentrations, 15–16
- Diprivan®, 15, 22, 26, 41
- dosing for TIVA
 - anaesthetic drug modelling systems, 60
 - clinical practice illustration, 60–1
 - considerations when using pharmacokinetic models, 61
 - dose requirements, 53–4
 - EC50 (effective concentration 50), 53–4
 - induction approaches, 54–6
 - MAC equivalent for TIVA, 53
 - maintenance of anaesthesia, 59–60
 - misconceptions about, 55–6
 - recovery from TIVA, 60
 - speeding up induction with TCI, 57–9
 - training, 52–3
 - units for TCI drug concentrations, 53
 - using TCI for induction and maintenance, 56–7
- droperidol, 46
- drug elimination
 - context sensitive half-time, 19–21
- Dynamic Gas Scavenging System (DGSS), 150
- EC₅₀ (effective concentration 50), 1, 11, 53–4
- EEG
 - canonical univariate parameter (CUP) analysis, 18
 - EEG monitoring
 - depth of anaesthesia, 65
 - limitations, 69
 - patterns under TCI TIVA, 65–6
 - EEG monitors, 44
 - effect compartment
 - definition, 8
 - keo and, 8
 - to effect, 11
 - effect compartment control (TCIE), 9
 - effect equilibration constant. *See* keo
- effect site, 16
- effect-site concentration
 - versus blood concentration, 16
- effect-site control, 16–17
- elderly patients and TIVA
 - advantages of TIVA in the elderly, 124
 - cardiovascular implications, 127–8
 - case scenario, 124
 - clinical considerations, 129
 - clinical scenario, 130
 - factors affecting
 - pharmacodynamics, 128–9
 - impact of changes in lean and fat mass, 128
 - impact of changes in liver and renal function, 128
 - impact of respiratory changes with aging, 127
 - pharmacokinetic models for the elderly, 129
 - pharmacokinetics in the elderly, 125–7
 - physiological changes with advancing age, 124
 - plasma proteins in the elderly, 128
 - post-operative cognitive dysfunction, 126
 - target-controlled infusion (TCI), 124–5
 - three-compartment model in the elderly, 126–7
- elimination half-life, 20
- E_{max} model, 11
- emergence agitation and delirium, 95–6
- emergency surgery
 - areas of concern for emergency surgery patients, 106–10
 - assumption that the patient has a full stomach, 106–7
 - effects of blood loss during TCI, 109
 - intubation and TIVA, 107–8
 - obstetric surgery, 109–10
 - rapid sequence induction (RSI), 106–7
 - risk of pulmonary aspiration, 106–7
 - role of TIVA, 106
 - test of anaesthetic technique, 106
 - use of TIVA on trauma patients, 108–9
- enflurane, 148
- enhanced recovery after surgery (ERAS) protocols, 107
- environmental impacts
 - anthropogenic greenhouse effect, 147
 - atmospheric characteristics of volatile anaesthetics, 148–9
 - butterfly effect (Chaos theory), 146

Index

- carbon dioxide equivalent (CO₂e)
 production by the UK NHS, 149
 carbon footprint of anaesthetic gas
 use, 149–50
 ecological economics approach,
 150–1
 ecological footprint of anaesthetic
 gas use, 149–50
 ecologically responsible anaesthesia,
 149–50
 effect of anaesthetic gases on
 radiative forcing, 146–7
 effects of climate change on human
 health, 146
 energy budget of the Earth, 146–7
 environmental cost of inhalational
 anaesthesia, 147
 evidence for climate change, 146
 extent of propofol wastage, 151
 global warming potential (GWP) of
 volatile anaesthetics, 148–9
 greenhouse gas emissions by the
 healthcare sector, 146
 greening the operating theatre,
 151–2
 Kyoto Protocol, 148–9
 life cycle analysis, 150
 Montreal Protocol, 148
 operating theatre scavenging
 systems, 150
 ozone-depleting effects of some
 volatile anaesthetics, 147
 ozone-depleting potential (ODP) of
 volatile anaesthetics, 148
 PBT index, 151
 volatile anaesthetics contribute to
 the greenhouse effect, 147
 waste anaesthetic gases, 150
 epidural analgesia, 86
 pre-operative concerns, 86
 TIVA benefits, 86
 ex utero intra-partum (EXIT)
 procedures, 144
 fat free mass (FFM), 133–4
 fentanyl, 19, 41
 concerns, 89
 context sensitive half-life, 35
 context sensitive half-time, 20
 TIVA benefits, 89
 transition opioid, 90–1
 transitioning, 89
 use for sedation, 156
 use in pregnant patients, 141–2
 use in TCI, 163
 food allergies
 propofol cross-reactivity, 26
 GABAA receptor
 target of propofol, 22–3
 gabapentin
 analgesic properties, 83
 mode of action, 83
 opioid-sparing adjuvant, 102–3
 pre-operative concerns, 83
 timing/dosage, 83
 Gepts model, 32, 36
 glycine receptors
 action of propofol, 23
 glycopyrrrolate, 103
 halothane, 147, 148
 Hill equation, 164
 histamine, 73
 hydraulic model, 5
 hydromorphone
 transition opioid, 91
 hyperpolarisation-activated cation
 (HCN) channel, 23
 hypertriglyceridaemia
 propofol induced, 26–7
 hypnotic drugs
 synergism with opioids, 96–7
 hysteresis, 101, 125
 hysteresis loops measurement method,
 8–9
 ibuprofen, 82, 102
 ideal body weight (IBW), 133
 Imed 929 infusion pump, 49
 inhalational anaesthesia
 minimum alveolar concentration
 (MAC), 1
 inhalational anaesthetic agents
 toxic effects on the body, 1
 isoflurane, 148, 149, 150
 Jackson, Michael, 155–6
 James formula, 43
 Kenny, Gavin, 14
 keo
 deciding on the correct keo to use for
 propofol, 34
 definition, 6–8
 effect compartment to effect, 11
 influence of patient parameters,
 10–11
 methods of measurement, 8–9
 origin of the terminology, 8
 use in TCI, 9–10
 value for different drugs, 125
 ketamine, 44
 adjuvant medication in TIVA, 75–6
 analgesic properties, 87–8
 concerns, 88
 mechanism of action, 88
 opioid-sparing adjuvant, 102–3
 recovery from TIVA, 102
 timing/dosage, 88
 TIVA benefits, 87–8
 use for sedation, 157
 ketorolac, 82, 102
 lean body mass (LBM)
 calculation, 43
 lean body weight (LBW), 133
 lidocaine, 87
 adjuvant medication in TIVA, 76
 concerns, 87
 mechanism of action, 87
 opioid-sparing adjuvant, 102–3
 timing/dosage, 87
 TIVA benefits, 87
 local anaesthetics, 85–7
 local infiltration of local anaesthetics,
 85–7
 pre-operative concerns, 87
 TIVA benefits, 86–7
 low flow anaesthesia (LFA), 150
 Lundy, John S., 73
 MAC (minimum alveolar
 concentration)
 equivalent for TIVA, 53
 magnesium
 adjuvant medication in TIVA, 75
 opioid-sparing adjuvant, 102–3
 Maitre model, 32, 36
 malignant hyperpyrexia, 140
 malignant hyperthermia
 risk with inhalational agents, 1
 mammillary model, 31
 Marsh model, 17–18, 31, 33
 comparison with the Schnider
 model, 34–5
 memory
 amnestic property of propofol, 24
 methadone
 concerns, 90
 mechanism of action, 90
 timing/dosage, 90
 TIVA benefits, 89
 transitioning, 90
 microbial growth in propofol, 25–6
 midazolam
 use for sedation, 156
 use in pregnant patients, 143
 minimum alveolar concentration (MAC)
 definition, 1
 Minto model, 32, 35
 Molina, Mario, 148
 morphine, 19, 35, 44, 102
 keo, 11
 transition opioid, 91
 use for sedation, 156
 myasthenia gravis, 140
 Narcotrend index, 66
 Navigator (GR Healthcare), 60

- neural inertia, 101–2
neurolept anaesthesia, 46
neurolept analgesia, 46
neuromodulators
 analgesic properties, 83
neuromuscular block (NMB)
 use in TIVA, 44
neuronal apoptosis with intravenous
 agents, 164
neurotoxicity
 risk in inhalation anaesthesia, 1
nitrous oxide (N₂O), 18, 149
NMDA receptor
 target of propofol, 23
nociception monitoring, 69
normal fat mass (NFM), 134
NSAIDs (non-steroidal anti-
 inflammatory drugs), 19
 analgesic properties, 82
 intravenous formulations, 102
 mechanism of action, 82
 timing/dosage, 82
- obese children
 performing TIVA, 117
obese patients
 adjusted body weight (ABW), 134
 applied pharmacokinetics, 134–6
 approaches for TIVA and TCI, 132
 BMI classification, 132, 133
 choice of size descriptor for drug
 dosing, 133–4
 dexmedetomidine
 pharmacokinetics, 136
 dosing strategies, 133
 fat free mass (FFM), 133–4
 ideal body weight (IBW), 133
 impact of cardiovascular changes,
 132
 lean body weight (LBW), 133
 normal fat mass (NFM), 134
 propofol pharmacokinetics, 134–5
 remifentanyl pharmacokinetics, 135
 respiratory system issues, 132
 total body weight (TBW), 133
 use of pharmacokinetic models,
 36–7
obstetrics. *See* pregnant patients
Ohmeda 9000 syringe pump, 47, 49
On-Q pump, 86
open TCI systems, 16, 48
 effect-site control, 16–17
opioid drugs
 analgesic drugs, 19
 analgesic properties, 84–5
 pharmacokinetic models, 35–6
 receptors, 84
 synergism with hypnotics, 96–7
 timing/dosage, 84–5
 transition opioids, 87, 90–1
- oxycodone, 84
 pre-operative concerns, 85
 timing/dosage, 84–5
oxycontin, 84
 pre-operative concerns, 85
 timing/dosage, 84–5
oxytocin, 144
- paediatric parameter sets, 164
paediatric patients
 intranasal dexmedetomidine, 75
 t_{1/2}keo (equilibration half-time),
 163–4
 use of pharmacokinetic models, 36
paediatric TIVA
 age considerations, 111
 body composition of children, 111
 clinical scenarios, 118–19
 depth of anaesthesia monitoring,
 115
 differences between children and
 adults, 111–13
 distribution to the effect site, 111–13
 drug delivery, 116
 effects of organ dysfunction, 111
 establishing TIVA after inhalational
 induction, 117
 indications, 111
 infusion regimes, 116
 injection pain with propofol, 117
 manipulating adult TCI pumps for
 children, 117–18
 manual infusion schemes for
 adolescents, 119
 manual infusion schemes for
 children, 119
 manual infusion schemes for infants,
 119
 obese children, 117
 parameter sets for propofol, 115
 parameter sets for remifentanyl, 115
 practical approach, 115–19
 propofol, 113–14
 ready mixes of drugs, 119–20
 remifentanyl, 114–15, 117
 size and drug clearance, 111
pancreatitis
 propofol induced, 26–7
paracetamol, 19
 analgesic properties, 81–2
 intravenous dosage, 102
 mechanism of action, 81
 pre-operative concerns, 81–2
 timing/dosage, 81
parecoxib, 82
patient-controlled sedation, 158–9
patient factors
 influence on pharmacokinetic
 models, 36–7
patient parameters
 influence on keo, 10–11
Patient State Index (PSI), 66
peripheral nerve blocks (PNB), 85–6
 pre-operative concerns, 86
 TIVA benefits, 85–6
pethidine, 19, 44
 use for sedation, 156
pharmacokinetic models
 comparison of models, 17–19
 considerations when using, 61
 deciding which model to use, 38
 development of, 48–9
 effects of drug interactions during
 TIVA, 38
 elderly people, 129
 Gepts model for sufentanil, 36
 influence of patient factors, 36–7
 Maitre model for alfentanil, 36
 mammillary model, 31
 Marsh model, 17–18, 33, 34–5
 Minto model for remifentanyl, 35
 naming of models, 33
 no model is perfect, 37–8
 obese patients, 36–7
 opioid drug models, 35–6
 paediatric patients, 36
 parameter sets for TCI, 31
 predicting drug concentration with
 TIVA, 31
 problems with predicting propofol
 effect-site concentration, 34
 propofol models, 16, 33–5
 range of suitable drugs, 36
 Schneider model, 17, 18, 33–5
 Scott model for alfentanil, 35–6
 three-compartment models, 31
 use in TCI, 31–2
 when only one or no TCI device is
 available, 37
 White model, 18
pharmacokinetic simulation
 Tivatrain programme, 54
pharmacokinetics
 elderly people, 125–7
 obese patients, 134–6
 propofol, 23–4
pharmacokinetics of TIVA, 5–12
 compartments, 5–6
 definition of keo, 6–8
 effect compartment, 8
 effect compartment to effect, 11
 keo measurement methods, 8–9
 keo terminology, 8
 TCI and keo, 9–10
phenoperidine, 46
Pierce, J.M.T., 149
post-operative cognitive dysfunction,
 67–9
 elderly patients, 126
post-operative delirium, 68

Index

- post-operative infections
 microbial growth in propofol, 25–6
- post-operative nausea and vomiting (PONV), 1, 74, 76, 84, 96
 anti-emetic administration, 103
 anti-emetic property of propofol, 25
 drugs associated with, 103
- post-operative pain, 1
- pregabalin
 analgesic properties, 83
 mode of action, 83
 opioid-sparing adjuvant, 102–3
 pre-operative concerns, 83
 timing/dosage, 83
- pregnant patients
 dexmedetomidine, 141
 emergency obstetric surgery, 109–10
 ex utero intra-partum (EXIT)
 procedures, 144
 fentanyl, 141–2
 fetal effects of drugs, 140
 fetal procedures, 144
 individual drugs and their uses,
 140–3
 labour pain relief, 140
 midazolam, 143
 obstetric case scenarios, 164–8
 patient-controlled analgesia (PCA),
 140
 pharmacokinetic and
 pharmacodynamic
 considerations, 139–40
 physiological changes and TIVA,
 139
 physiological changes that may
 require adjustment of drug
 dosage, 139–40
 placental transfer of drugs, 140
 propofol, 140–1
 remifentanyl, 142–3
 sufentanyl, 143
 uterine tone indications for TIVA,
 143–4
- processed EEG monitors, 44
- propofol
 activity, 22
 adverse effects and clinical issues,
 25–7
 amnesic property, 24
 anti-emetic action, 25
 anti-microbial additive, 25–6
 anti-tumour properties, 1
 basic pharmacology, 22–3
 cardiovascular effects, 25
 central nervous system effects, 24–5
 clinical pharmacology, 23–5
 combination with remifentanyl, 20
 comparison of the Marsh and
 Schnider models, 34–5
- cross-reactivity with food allergies, 26
 deciding on the correct keo to use, 34
 extent of wastage, 151
 history of development, 22
 hypertriglyceridaemia associated
 with, 26–7
 injection pain, 117
 Marsh model, 17–18
 mechanism of action, 22–3
 metabolism, 23
 pain on injection, 26
 pancreatitis associated with, 26–7
 parameter sets for paediatric TIVA,
 115
 pharmacodynamics, 24–5
 pharmacokinetic models, 16, 33–5
 pharmacokinetic parameter sets, 31
 pharmacokinetics, 23–4
 pharmacokinetics for obese patients,
 134–5
 potential drug interactions, 23
 preparations, 40–1
 receptor targets, 22–3
 respiratory effects, 25
 risk of propofol infusion syndrome
 (PRIS), 27
 Schnider model, 18
 standard syringes with electronic
 tags, 47–8
 structure, 22
 support of microbial growth, 25–6
 synergism with remifentanyl, 96–7
 titration, 21, 45
 use for emergency surgery, 107
 use for sedation, 89
 use in paediatric TIVA, 113–14
 use in pregnant patients, 140–1
 use of adjuvant medications in
 TIVA, 73
 White model, 18
- propofol infusion syndrome (PRIS)
 risk factors, 27
- PRO-TECT II trial, 25
- qCON index, 65, 66, 67
qNOX index, 65, 66, 67, 69
- rapid sequence induction (RSI)
 emergency surgery cases, 106–7
- recovery
 advantages of TIVA, 1
 recovery from TIVA, 60
 advantages of TIVA during the
 emergence phase, 95–6
 allow for hysteresis, 101
 check for paralysis and
 reverse or antagonise, 103
 consider anti-emetic administration,
 103
- consider opioid-sparing analgesic
 adjuvants, 102–3
 emergence agitation and delirium,
 95–6
 ensure adequate analgesia, 102
 factors influencing quality of
 recovery, 95
 judging the timing of emergence
 correctly, 96–102
 management of a smooth recovery,
 103–4
 neural inertia, 101–2
 post-operative nausea and vomiting
 (PONV), 96
 use of decrement time to guide
 anaesthetic management, 97–101
 use of depth of anaesthesia
 monitoring, 96
 utilise the synergism between
 hypnotics and opioids, 96–7
 working with ketamine, 102
- remifentanyl, 87
 analgesic properties, 19
 decrement time, 20, 100
 elimination half-life, 20
 keo, 11
 Minto model, 35
 parameter sets for paediatric TIVA,
 115
 pharmacokinetic parameter sets, 31
 pharmacokinetics for obese patients,
 135
 preparations, 41
 synergism with propofol, 96–7
 titration, 45
 TIVA benefits, 89
 transitioning, 89
 use as adjunct in paediatric TIVA,
 117
 use for sedation, 156
 use in paediatric TIVA, 114–15
 use in pregnant patients, 142–3
- remimazolam, 156–7
- respiratory system
 effects of propofol, 25
- responsiveness
 suppression in anaesthesia, 73–4
- rocuronium, 103, 107
- Rowland, Sherwood, 148
- safety aspects of syringe pumps for
 TIVA, 49–50
- Schnider model, 17, 18, 31, 33–4
 comparison with the Marsh model,
 34–5
- Scott model, 32, 35–6
- sedation
 candidate drugs, 155–7
 case of Michael Jackson, 155–6

- computer-assisted sedation systems, 158–9
- current practice, 154
- definitions, 154–5
- dexmedetomidine, 157
- expectations of patients and clinicians, 154–5
- fentanyl, 156
- ketamine, 157
- mastering sedation, 157–8
- midazolam, 156
- monitoring, 158
- morphine, 156
- patient characteristics, 157–8
- patient-controlled sedation, 158–9
- pethidine, 156
- procedure characteristics, 158
- propofol, 156
- reasons for using, 154–5
- remifentanyl, 156
- remimazolam, 156–7
- SedLine™ monitor, 44, 96
- Sellick manoeuvre, 106
- serotonin syndrome, 85
- setting up TIVA, 40–5
 - drug preparation and infusion set up, 40–2
 - EEG monitors, 44
 - lean body mass (LBM) calculation, 43
 - pump programming and features, 42–5
 - risk of awareness, 44
 - target-controlled infusion (TCI) devices, 40
 - titration, 43–4, 45
 - use of neuromuscular block (NMB), 44
- sevoflurane, 1, 95–6, 148, 149, 150
- SmartPilot® (Dräger), 60
- SNRIs, 85
- SSRIs, 85
- state entropy (SE) index, 66
- steroids
 - analgesic properties, 83–4
- sufentanil, 19, 41
 - context sensitive half-time, 20, 89
 - Gepts model, 36
 - pharmacokinetic parameter sets, 31
 - timing/dosage, 89
 - titration, 45
 - TIVA benefits, 89
 - transitioning, 89
 - use in pregnant patients, 143
 - use in TCI, 163
- sugammadex, 103, 107
- Sutcliffe, Nick, 3
- suxamethonium, 107
- syringe pumps
 - algorithms used to programme pumps, 46–7
 - before programmable syringe pumps, 46
 - development of algorithms, 48–9
 - development of the Diprifusor™ module, 47
 - history of anaesthetic drug administration, 46
 - mechanics, 46–7, 49
 - Ohmeda 9000 pump, 47
 - programming, 49–50
 - safety aspects, 49–50
 - stages of development, 47–9
 - standard propofol syringes with electronic tags, 47–8
 - stepper motor, 46–7
 - TIVA delivery sets, 50–1
 - use of depth of anaesthesia monitoring, 51
 - volumetric roller pumps, 49
- $t_{1/2keo}$, 18, 125
- tapentadol
 - analgesic properties, 85
 - pre-operative concerns, 85
 - receptors, 85
 - timing/dosage, 85
 - TIVA benefits, 85
- target-controlled infusion (TCI), 1
 - ability to make proportional changes, 16
 - accuracy of, 15–16
 - blood versus effect-site concentrations, 16
 - comparison of pharmacokinetic models, 17–19
 - delay between blood concentration and drug effect, 7–8
 - development of TCI systems, 14–15
 - development of the Diprifusor™, 15
 - drug preparation and infusion set-up, 40–2
 - effect-site control, 16–17
 - elderly patients, 124–5
 - history of development, 14
 - induction and maintenance of anaesthesia, 56–7
 - keo and, 7–8
 - manipulating adult TCI pumps for children, 117–18
 - Marsh model, 17–18
 - open TCI systems, 16
 - origins of misconceptions about, 14
 - pharmacokinetic parameter sets, 31
 - predicted versus measured concentrations, 15–16
 - pump programming and features, 42–5
 - Schnider model, 17, 18
 - titration, 21
 - use of keo, 9–10
 - use of pharmacokinetic models, 31–2
 - when only one TCI device is available, 37
 - White model, 18
 - See also* syringe pumps
- target-controlled inhalational anaesthesia (TCA), 150
- TCAs (tricyclic antidepressants), 85
- therapeutic index of anaesthetic drugs, 14
- thiopental, 46, 140
 - use for emergency surgery, 107
- three-compartment model, 5–6, 31
- elderly people, 126–7
- time-delay constant. *See* keo
- time to peak effect (TTPE)
 - use in the Schnider model, 18
- time to peak effect (TTPE) method, 9
- titration
 - anaesthetic agents, 21
 - during TIVA, 43–4, 45
 - importance in anaesthesia, 14
 - transition opioids, 90
- TIVA. *See* total intravenous anaesthesia (TIVA)
- Tivatrainer pharmacokinetic simulation programme, 54
- total body weight (TBW), 133
- total intravenous anaesthesia (TIVA)
 - advantages over inhalational anaesthesia, 1
 - analgesic supplements, 19
 - balanced anaesthesia, 19
 - context sensitive half-time, 19–21
 - delivery sets, 50–1
 - depth of anaesthesia monitoring, 51
 - development of TCI systems, 14–15
 - modes of delivery, 63
 - predicting drug concentrations, 31
 - reasons for gaining competency in, 3
 - reasons for not choosing to use, 1–3
 - risk of awareness under anaesthesia, 63–5
 - titration, 21
- training
 - dosing for TIVA, 52–3
- tramadol
 - analgesic properties, 85
 - pre-operative concerns, 85
 - receptors, 85
 - timing/dosage, 85
 - TIVA benefits, 85

Index

- | | | |
|---|-----------------------------|--|
| trans-nasal humidified intra-nasal ventilatory exchange (THRIVE), 107 | morphine, 91 | White model, 18 |
| transition opioids, 90–1 | titration, 90 | Wolff–Parkinson–White syndrome, 143 |
| fentanyl, 90–1 | valdecoxib, 82 | Wong, G.T.C., 14 |
| hydromorphone, 91 | volumetric roller pumps, 49 | World Health Organization Model Lists of Essential Medicines, 75 |